After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum?

[cafead]

via Atara Biotherapeutics scored a world-first approval for an off-the-shelf T cell therapy when the European Commission greenlit Ebvallo to treat an ultra-rare type of blood cancer in 2022.

article source

 

[anonymous]

Atara is ready to go belly up. Company is In a world of trouble, awful leadership that is taking them nowhere. Might as well stop now and give shareholders their money back